SK2982003A3 - Preparation of risperidone - Google Patents
Preparation of risperidone Download PDFInfo
- Publication number
- SK2982003A3 SK2982003A3 SK2982003A SK2982003A SK2982003A3 SK 2982003 A3 SK2982003 A3 SK 2982003A3 SK 2982003 A SK2982003 A SK 2982003A SK 2982003 A SK2982003 A SK 2982003A SK 2982003 A3 SK2982003 A3 SK 2982003A3
- Authority
- SK
- Slovakia
- Prior art keywords
- risperidone
- isopropanol
- ray powder
- powder diffraction
- risperidone form
- Prior art date
Links
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 title claims abstract description 234
- 229960001534 risperidone Drugs 0.000 title claims abstract description 233
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 73
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 78
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 46
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 41
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 39
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- 239000002904 solvent Substances 0.000 claims description 34
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 30
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 28
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 21
- 238000001556 precipitation Methods 0.000 claims description 21
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 10
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- 150000002576 ketones Chemical class 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- MRMGJMGHPJZSAE-UHFFFAOYSA-N 6-fluoro-3-piperidin-4-yl-1,2-benzoxazole Chemical compound N=1OC2=CC(F)=CC=C2C=1C1CCNCC1 MRMGJMGHPJZSAE-UHFFFAOYSA-N 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- -1 tetrtahydrofuran Chemical compound 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 5
- CMWCQQUYLPYOMY-UHFFFAOYSA-N 3-(2-chloroethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound C1CCCN2C(=O)C(CCCl)=C(C)N=C21 CMWCQQUYLPYOMY-UHFFFAOYSA-N 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 2
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 13
- 239000006185 dispersion Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 239000012065 filter cake Substances 0.000 description 8
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 3
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- USVZHTBPMMSRHY-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-chlorophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Cl USVZHTBPMMSRHY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000001309 chloro group Chemical class Cl* 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 238000001144 powder X-ray diffraction data Methods 0.000 description 1
- 229940106887 risperdal Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22536100P | 2000-08-14 | 2000-08-14 | |
| US24326300P | 2000-10-25 | 2000-10-25 | |
| PCT/US2001/025387 WO2002014286A1 (en) | 2000-08-14 | 2001-08-14 | Preparation of risperidone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK2982003A3 true SK2982003A3 (en) | 2004-10-05 |
Family
ID=26919535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK2982003A SK2982003A3 (en) | 2000-08-14 | 2001-08-14 | Preparation of risperidone |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6750341B2 (hu) |
| EP (2) | EP1317434A4 (hu) |
| JP (3) | JP3751942B2 (hu) |
| KR (2) | KR20080028513A (hu) |
| AT (1) | ATE401313T1 (hu) |
| AU (1) | AU2001284880A1 (hu) |
| CA (1) | CA2419314C (hu) |
| CZ (1) | CZ2003668A3 (hu) |
| DE (1) | DE60134899D1 (hu) |
| ES (1) | ES2310410T3 (hu) |
| HR (1) | HRP20030154B1 (hu) |
| HU (1) | HUP0302874A2 (hu) |
| IL (2) | IL154417A0 (hu) |
| IS (1) | IS6713A (hu) |
| MX (1) | MXPA03001337A (hu) |
| NZ (1) | NZ524554A (hu) |
| PL (1) | PL365608A1 (hu) |
| PT (1) | PT1783118E (hu) |
| SK (1) | SK2982003A3 (hu) |
| WO (1) | WO2002014286A1 (hu) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7666445B2 (en) * | 2000-10-20 | 2010-02-23 | The Trustees Of The University Of Pennsylvania | Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use |
| BR0306204A (pt) * | 2002-08-30 | 2004-09-08 | Torrent Pharmaceuticals Ltd | Processo melhorado para a preparação de risperidona |
| KR20040034996A (ko) * | 2002-10-18 | 2004-04-29 | 한미약품 주식회사 | 리스페리돈의 개선된 제조방법 |
| CN100390146C (zh) | 2002-11-13 | 2008-05-28 | 斯索恩有限公司 | 制备利培酮的方法和用于该方法的中间体 |
| US20040180935A1 (en) * | 2003-02-28 | 2004-09-16 | Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Inc. | Crystalline form Z of rabeprazole sodium and process for preparation thereof |
| AU2003245028A1 (en) * | 2003-04-16 | 2004-11-04 | Hetero Drugs Limited | A novel crystalline form of risperidone |
| DK1673370T3 (da) | 2003-10-16 | 2009-12-07 | Symed Labs Ltd | Krystallingsk form af linezolid |
| EP1711124A4 (en) * | 2004-01-12 | 2011-06-01 | Univ Pennsylvania | LONG-TERM RELEASE PREPARATIONS AND METHODS OF USE THEREOF |
| US8329203B2 (en) * | 2004-01-12 | 2012-12-11 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| US8221778B2 (en) * | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| ES2294494T3 (es) * | 2004-04-19 | 2008-04-01 | Symed Labs Limited | Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados. |
| HUP0401379A3 (en) * | 2004-07-08 | 2006-04-28 | Richter Gedeon Vegyeszet | Process for the preparation of risperidon |
| JP2008512471A (ja) * | 2004-09-08 | 2008-04-24 | ダーマトレンズ，インコーポレイティド | 疎水性生体活性物質の経皮送達 |
| HUP0402163A2 (en) * | 2004-10-25 | 2006-05-29 | Richter Gedeon Vegyeszet | Process for the preparation of risperidone |
| US20090075974A1 (en) * | 2005-04-27 | 2009-03-19 | Umn Pharma Inc. | Agent for prophylaxis and treatment of pancreatitis |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| WO2007093870A2 (en) * | 2006-02-15 | 2007-08-23 | Orchid Chemicals & Pharmaceuticals Limited | A process for the preparation of risperidone |
| US7820816B2 (en) * | 2006-08-23 | 2010-10-26 | Teva Pharmaceutical Industries Ltd. | Process for the synthesis of CMHTP and intermediates thereof |
| BRPI0811319A2 (pt) | 2007-05-25 | 2015-02-10 | Tolmar Therapeutics Inc | Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento |
| BRPI1007173A2 (pt) | 2009-01-20 | 2016-02-23 | Los Angeles Biomed Res Inst | composição farmacêutica compreendendo ácido sórbico e benzóico e seus derivados que melhora a atividade de um neurofármaco, e seu uso, formulação farmacêutica e método de mitigação de um ou mais sintomas de um distúrbio neuropsiquiátrico |
| CN102786521B (zh) * | 2011-05-18 | 2016-01-13 | 中国医学科学院药物研究所 | 利培酮晶iii型物质及制备方法与在药品和保健品中应用 |
| CN105367570B (zh) * | 2015-12-08 | 2017-10-10 | 天津市亨必达化学合成物有限公司 | 一种利培酮晶i型物质的制备方法 |
| US11008277B2 (en) | 2016-06-13 | 2021-05-18 | Syneurx International (Taiwan) Corp. | Co-crystals of sodium benzoate and uses thereof |
| RU2022101542A (ru) | 2016-06-13 | 2022-02-03 | Сайньюрекс Интернэшнл (Тайвань) Корп. | Сокристаллы бензоата лития и их применения |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| US5158952A (en) * | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| ES2050069B1 (es) | 1992-07-10 | 1994-12-16 | Vita Invest Sa | Procedimiento para la obtencion de 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-il)piperidino)etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido(1,2-a) pirimidin-4-ona. |
| ES2074966B1 (es) | 1994-02-11 | 1996-06-16 | Vita Invest Sa | Procedimiento para la obtencion de 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il)piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a)pirimidin-4-ona. |
| AU723563B2 (en) * | 1996-01-26 | 2000-08-31 | Pharmacia & Upjohn Company | Use of a combination of delavirdine and one or more protease inhibitors in HIV-1 infected patients |
| TW487572B (en) * | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| IT1294931B1 (it) * | 1997-09-22 | 1999-04-23 | Sigma Tau Ind Farmaceuti | Derivati della 2-amminotetralina procedimento per la loro preparazione e composizioni farmaceutiche che li contengono, attive nella |
| ATE264329T1 (de) | 2000-05-05 | 2004-04-15 | Rpg Life Sciences Ltd | Verfahren zur herstellung von antipsychotischem 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1- |
| US20020115672A1 (en) * | 2000-08-08 | 2002-08-22 | Barnaba Krochmal | Preparation of risperidone |
| US20020193386A1 (en) | 2002-03-28 | 2002-12-19 | Inigo Pfeiffer | Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof |
-
2001
- 2001-08-14 SK SK2982003A patent/SK2982003A3/sk not_active Application Discontinuation
- 2001-08-14 AU AU2001284880A patent/AU2001284880A1/en not_active Abandoned
- 2001-08-14 KR KR1020087005461A patent/KR20080028513A/ko not_active Application Discontinuation
- 2001-08-14 HU HU0302874A patent/HUP0302874A2/hu unknown
- 2001-08-14 WO PCT/US2001/025387 patent/WO2002014286A1/en not_active Application Discontinuation
- 2001-08-14 PL PL01365608A patent/PL365608A1/xx not_active Application Discontinuation
- 2001-08-14 CZ CZ2003668A patent/CZ2003668A3/cs unknown
- 2001-08-14 EP EP01963971A patent/EP1317434A4/en not_active Withdrawn
- 2001-08-14 JP JP2002519429A patent/JP3751942B2/ja not_active Expired - Fee Related
- 2001-08-14 EP EP08011131A patent/EP1982980A1/en not_active Withdrawn
- 2001-08-14 DE DE60134899T patent/DE60134899D1/de not_active Revoked
- 2001-08-14 MX MXPA03001337A patent/MXPA03001337A/es active IP Right Grant
- 2001-08-14 US US09/929,808 patent/US6750341B2/en not_active Expired - Fee Related
- 2001-08-14 KR KR1020037002036A patent/KR100818875B1/ko not_active IP Right Cessation
- 2001-08-14 AT AT07001138T patent/ATE401313T1/de not_active IP Right Cessation
- 2001-08-14 ES ES07001138T patent/ES2310410T3/es not_active Expired - Lifetime
- 2001-08-14 PT PT07001138T patent/PT1783118E/pt unknown
- 2001-08-14 NZ NZ524554A patent/NZ524554A/en unknown
- 2001-08-14 CA CA002419314A patent/CA2419314C/en not_active Expired - Fee Related
- 2001-08-14 IL IL15441701A patent/IL154417A0/xx unknown
-
2003
- 2003-02-11 IS IS6713A patent/IS6713A/is unknown
- 2003-02-12 IL IL154417A patent/IL154417A/en not_active IP Right Cessation
- 2003-03-04 HR HR20030154A patent/HRP20030154B1/xx not_active IP Right Cessation
- 2003-09-23 US US10/669,272 patent/US7256195B2/en not_active Expired - Fee Related
-
2005
- 2005-08-25 JP JP2005244095A patent/JP2006028192A/ja not_active Withdrawn
-
2007
- 2007-11-14 JP JP2007296023A patent/JP2008056699A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL154417A (en) | 2008-11-03 |
| EP1982980A1 (en) | 2008-10-22 |
| IL154417A0 (en) | 2003-09-17 |
| EP1317434A1 (en) | 2003-06-11 |
| HRP20030154B1 (en) | 2009-03-31 |
| MXPA03001337A (es) | 2005-06-30 |
| US7256195B2 (en) | 2007-08-14 |
| WO2002014286A9 (en) | 2003-03-27 |
| JP2004506622A (ja) | 2004-03-04 |
| ES2310410T3 (es) | 2009-01-01 |
| KR100818875B1 (ko) | 2008-04-01 |
| CA2419314A1 (en) | 2002-02-21 |
| PT1783118E (pt) | 2008-08-19 |
| JP2008056699A (ja) | 2008-03-13 |
| CA2419314C (en) | 2006-07-11 |
| US6750341B2 (en) | 2004-06-15 |
| JP3751942B2 (ja) | 2006-03-08 |
| CZ2003668A3 (en) | 2004-04-14 |
| PL365608A1 (en) | 2005-01-10 |
| EP1317434A4 (en) | 2005-06-22 |
| ATE401313T1 (de) | 2008-08-15 |
| KR20080028513A (ko) | 2008-03-31 |
| US20040229905A1 (en) | 2004-11-18 |
| NZ524554A (en) | 2005-07-29 |
| DE60134899D1 (de) | 2008-08-28 |
| US20020115673A1 (en) | 2002-08-22 |
| IS6713A (is) | 2003-02-11 |
| HUP0302874A2 (hu) | 2003-12-29 |
| HRP20030154A2 (en) | 2005-04-30 |
| KR20030022389A (ko) | 2003-03-15 |
| AU2001284880A1 (en) | 2002-02-25 |
| JP2006028192A (ja) | 2006-02-02 |
| WO2002014286A1 (en) | 2002-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK2982003A3 (en) | Preparation of risperidone | |
| CZ2012879A3 (cs) | Způsob přípravy a čištění nových i známých polymorfů a solvátů dasatinibu | |
| TW201629060A (zh) | 一種週期素依賴性蛋白激酶抑制劑的羥乙基磺酸鹽、其結晶形式及製備方法 | |
| HUE024989T2 (hu) | Azaindol-származékok mint ABI és SRC protein kináz inhibitorok | |
| WO2009016653A1 (en) | Stable polymorphic form of paliperidone and process for its preparation | |
| US20020115672A1 (en) | Preparation of risperidone | |
| SK3092003A3 (en) | Process for the preparation of mesylates of piperazine derivatives | |
| NO843908L (no) | Fremgangsmaare for fremstilling av 4-alkyl-2(1h)-kinazolinon-1-alkansyrederivater | |
| JP5758010B2 (ja) | 酒石酸によるトリアジン誘導体エナンチオマーの分離 | |
| CZ2002759A3 (cs) | Meziprodukty pro přípravu derivátů chinolonkarboxylové kyseliny | |
| EA011748B1 (ru) | Способ получения рисперидона | |
| CA2535728C (en) | Preparation of risperidone | |
| NL8203035A (nl) | Spirothiazolidinylpiperazinederivaten. | |
| El-Gendy et al. | Synthesis and antihypertensive activity of certain Mannich Bases of 2-ethoxycarbonylindoles and 5 H-pyridazino [4, 5-b] indoles | |
| EP1783118B1 (en) | Preparation of risperidone | |
| US20060004199A1 (en) | Process for the preparation of pure 3-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one | |
| CA2549398A1 (en) | Preparation of risperidone | |
| ZA200301200B (en) | Preparation of risperidone. | |
| CA2496684A1 (en) | Crystalline solid famciclovir forms i, ii, iii and preparation thereof | |
| US20040209898A1 (en) | Process for the preparation of risperidone | |
| CA2807859A1 (en) | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |